Search Within

Urvi A Shah

Formats
  1. Meeting Abstract (136)
  2. Journal Article (38)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (4)
  6. Editorial (2)
  7. Book Section (1)
Groups
  1. CTCR Scholars (203)
  2. Department of Medicine (203)
  3. Hematologic Malignancies, Division of (203)
  4. Center for Hematologic Malignancies (156)
  5. Myeloma (155)
  6. Hematologic Malignancies Research (150)

More Groups

People
  1. Alexander Lesokhin (146)
  2. Sham Mailankody (141)
  3. Malin Hultcrantz (135)
  4. Neha Korde (133)
  5. Hani Hassoun (132)
  6. Carlyn Rose Tan (122)

More People

Years
  1. 2025 (10)
  2. 2024 (49)
  3. 2023 (44)
  4. 2022 (44)
  5. 2021 (16)
  6. 2020 (20)

More Years

Publications
  1. Blood (76)
  2. Clinical Lymphoma, Myeloma and Leukemia (42)
  3. Journal of Clinical Oncology (15)
  4. Blood Cancer Journal (9)
  5. Blood Advances (8)
  6. Biology of Blood and Marrow Transplantation (4)

More Publications

Publishers
  1. American Society of Hematology (84)
  2. Elsevier Inc. (52)
  3. American Society of Clinical Oncology (15)
  4. Nature Publishing Group (14)
  5. American Association for Cancer Research (6)
  6. American Medical Association (4)

More Publishers

Results (203)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Racial differences in proportion of myeloma cases attributable to modifiable risk factors in the United States, 2016-21
    Meeting Abstract

    Anuraj, A.; Rath, D.; Derkach, A.; Usmani, S. Z.; Shah, U. A.
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDACTM degrader, with dexamethasone in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Dhakal, B.; Yee, A. J.; Richardson, P. G.; Ailawadhi, S.; Chhabra, S.; Muchtar, E.; Berdeja, J. G.; Richard, S.; Matous, J.; Shah, U. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: Results from the phase 3 CARTITUDE-4 clinical trial
    Meeting Abstract

    Bar, N.; Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L. O.; Isufi, I.; Harrison, S. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • North American adult T-cell leukemia lymphoma has frequent mutations in CCR4 and responds in vitro to a small molecule CCR4 antagonist
    Meeting Abstract

    Liu, E.; Verma, A.; Pradhan, K.; Shah, U. A.; Shastri, A.; Guillen, E.; Sica, A.; Lauvau, G.; Janakiram, M.; Kassner, P. D.
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save